Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

Article Abstract:

Lovastatin can lower the risk of heart attack in people with high blood cholesterol, high C-reactive protein levels, or both. C-reactive protein is a marker of inflammation, and could be used to detect the early stages of heart disease in people who have no symptoms.

Physiological aspects

---

C-reactive proteins levels and outcomes after Statin therapy

Article Abstract:

Patients who have low C-reactive protein (CRP) levels after Statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of low-density lipoprotein (LDL) cholesterol. Strategies of lower cardiovascular risk with Statins are listed.

United States, Science & research, Research, Cardiovascular diseases, Patient outcomes, Risk factors, Statins

---

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS

Article Abstract:

Lovastatin appears to lower the risk of heart attack, angina and the need for revascularization procedures in people without heart disease but with low levels of high-density lipoprotein (HDL) cholesterol. This type of cholesterol protects against heart disease. Researchers randomly assigned 5,608 men and 997 women to take lovastatin or placebo every day in addition to a low-fat diet. After an average follow-up of five years, lovastatin reduced the risk of heart attack, angina and other cardiovascular events by 25% to 40%. The need for revascularization procedures such as angioplasty was also reduced.

Evaluation, Angina pectoris

Similar abstracts:

• Abstracts: Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes
• Abstracts: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
• Abstracts: Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
• Abstracts: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
• Abstracts: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS clinical trials group 5108 study

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.